CN101506376A - 前列腺特异性转录物及其在前列腺癌治疗和诊断中的应用 - Google Patents

前列腺特异性转录物及其在前列腺癌治疗和诊断中的应用 Download PDF

Info

Publication number
CN101506376A
CN101506376A CNA2007800252509A CN200780025250A CN101506376A CN 101506376 A CN101506376 A CN 101506376A CN A2007800252509 A CNA2007800252509 A CN A2007800252509A CN 200780025250 A CN200780025250 A CN 200780025250A CN 101506376 A CN101506376 A CN 101506376A
Authority
CN
China
Prior art keywords
sequence
gene
nucleic acid
prostate cancer
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800252509A
Other languages
English (en)
Chinese (zh)
Inventor
理查德·爱因斯坦
凯文·保尔·凯恩
马修·保罗·潘多
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ExonHit Therapeutics SA
Original Assignee
ExonHit Therapeutics SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ExonHit Therapeutics SA filed Critical ExonHit Therapeutics SA
Publication of CN101506376A publication Critical patent/CN101506376A/zh
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CNA2007800252509A 2006-07-03 2007-06-29 前列腺特异性转录物及其在前列腺癌治疗和诊断中的应用 Pending CN101506376A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81768606P 2006-07-03 2006-07-03
US60/817,686 2006-07-03

Publications (1)

Publication Number Publication Date
CN101506376A true CN101506376A (zh) 2009-08-12

Family

ID=38537749

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800252509A Pending CN101506376A (zh) 2006-07-03 2007-06-29 前列腺特异性转录物及其在前列腺癌治疗和诊断中的应用

Country Status (10)

Country Link
US (1) US20120141376A1 (enExample)
EP (1) EP2044216A2 (enExample)
JP (1) JP2009540852A (enExample)
KR (1) KR20090111307A (enExample)
CN (1) CN101506376A (enExample)
AU (1) AU2007271232A1 (enExample)
CA (1) CA2656140A1 (enExample)
IL (1) IL196184A0 (enExample)
WO (1) WO2008003656A2 (enExample)
ZA (1) ZA200900794B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108108590A (zh) * 2012-03-05 2018-06-01 阿克蒂克合伙公司 分析系统和方法
CN108135151A (zh) * 2015-09-02 2018-06-08 瑞泽恩制药公司 前列腺癌的啮齿动物模型
CN111383757A (zh) * 2020-03-04 2020-07-07 南京亿科人群健康研究院有限公司 一种计算机辅助开发包虫病诊断试剂盒的方法
CN113552350A (zh) * 2015-04-21 2021-10-26 基因泰克公司 用于前列腺癌分析的组合物和方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1007704A2 (pt) * 2009-05-12 2019-12-03 Koninklijke Philips Electronics N.V. fosfodiesterase 4d7 (pde4d7), para uso como um marcador para câncer de próstata maligno, sensível a hormônio; composição ou método de aquisição de dados ou imunoensaio para diagnosticar, detectar, monitorar ou prognosticar câncer de prostata maligno, sensível ao hormônio ou para diagnosticar, detectar, monitorar ou prognosticar a progressão para câncer de próstata maligno, sensível a hormônio; uso de pde4d7; imunoensaio para discriminar entre um tumor de próstata benigno e um câncer de próstata maligno, sensível a hormônio; método para identificar um indivíduo para elegibilidade para terapia contra câncer de próstata maligno, sensível a hormônio; imunoensaio para classificar um indivíduo ou corte de indivíduos com uma doença de câncer de próstata maligno, sensível a hormônio; composição farmacêutica inibitória para o tratamento ou prevenção de câncer de próstata maligno, sensível a hormônio; composição farmacêutica estimulatória; e; uso de um anticorpo específico para a proteína pde4d7 e/ou uma variante de anticorpo específica para a proteína pde4d7
DE102012203547A1 (de) * 2012-03-07 2013-09-12 Robert Bosch Gesellschaft Für Medizinische Forschung Mbh Antimikrobielle Peptide
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
CN114740202A (zh) 2014-03-28 2022-07-12 欧普科诊断有限责任公司 与前列腺癌的诊断有关的组合物和方法
KR101698654B1 (ko) 2014-12-24 2017-01-20 포항공과대학교 산학협력단 En2에 특이적으로 결합하는 dna 압타머 및 이의 용도
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
CA2982262A1 (en) 2015-04-29 2016-11-03 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
KR101777085B1 (ko) 2017-02-23 2017-09-11 주식회사 성균바이오텍 En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물
US11410748B2 (en) * 2018-02-22 2022-08-09 Liquid Biopsy Research LLC Methods for prostate cancer detection and treatment
EP3958879A4 (en) * 2019-04-25 2023-05-10 Actinium Pharmaceuticals, Inc. Compositions and methods of immunodepletion for the treatment of malignant and non-malignant hematological diseases

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2775984B1 (fr) * 1998-03-11 2006-09-15 Bioscreen Therapeutics Sa Criblage differentiel qualitatif
AU3305699A (en) * 1998-02-26 1999-09-15 Beckman Coulter, Inc. Prostate-specific membrane antigens and methods of making and using
WO2001055448A1 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
JP2005519606A (ja) * 2002-03-14 2005-07-07 エグゾニ・テラピューティック・ソシエテ・アノニム ヒトカリクレイン−２及びカリクレイン−３のバリアント並びにそれらの使用
WO2004113571A2 (en) * 2003-06-26 2004-12-29 Exonhit Therapeutics Sa Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108108590A (zh) * 2012-03-05 2018-06-01 阿克蒂克合伙公司 分析系统和方法
CN113552350A (zh) * 2015-04-21 2021-10-26 基因泰克公司 用于前列腺癌分析的组合物和方法
CN108135151A (zh) * 2015-09-02 2018-06-08 瑞泽恩制药公司 前列腺癌的啮齿动物模型
CN111383757A (zh) * 2020-03-04 2020-07-07 南京亿科人群健康研究院有限公司 一种计算机辅助开发包虫病诊断试剂盒的方法
CN111383757B (zh) * 2020-03-04 2023-08-25 南京亿科人群健康研究院有限公司 一种计算机辅助开发包虫病诊断试剂盒的方法

Also Published As

Publication number Publication date
US20120141376A1 (en) 2012-06-07
WO2008003656A2 (en) 2008-01-10
ZA200900794B (en) 2010-07-28
CA2656140A1 (en) 2008-01-10
AU2007271232A1 (en) 2008-01-10
JP2009540852A (ja) 2009-11-26
WO2008003656A3 (en) 2008-03-20
IL196184A0 (en) 2009-09-22
KR20090111307A (ko) 2009-10-26
EP2044216A2 (en) 2009-04-08

Similar Documents

Publication Publication Date Title
US7834163B2 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy
US20120141376A1 (en) Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
US20090053227A1 (en) Prostate Specific Genes and The Use Thereof in Design of Therapeutics
US7993830B2 (en) Prostate-specific gene for diagnosis, prognosis and management of prostate cancer
CN1964986A (zh) 用于鉴定、评价、预防和治疗卵巢癌的核酸分子和蛋白质
CA2267128A1 (en) Reagents and methods useful for detecting diseases of the prostate
CA2308029A1 (en) Reagents and methods useful for detecting diseases of the breast
US20080254031A1 (en) Tumor Specific Genes and Variant Rnas and Uses Thereof as Targets for Cancer Therapy and Diagnosis
JP2004532629A (ja) 癌・精巣抗原
US20110287010A1 (en) Diagnostic methods and markers
JP2005519606A (ja) ヒトカリクレイン−２及びカリクレイン−３のバリアント並びにそれらの使用
EP1575993A2 (en) Methods for treating patients and identifying therapeutics
US20020068036A1 (en) Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators
WO2002016939A2 (en) Methods of diagnosis of cancer and screening for cancer modulators
JP2006519589A5 (enExample)
JP2006519589A (ja) 癌における新規な組成物および方法
EP1410035A2 (en) Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators
US20030087245A1 (en) Uses of PBH1 in the diagnosis and therapeutic treatment of prostate cancer

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090812